Skip to main navigation
Close
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Blog
Mar 2, 2021
| Erica Klinger
Healthy Competition in the Office—Even When We’re Not in the Office
Press Release
Feb 25, 2021
| Rachel Schwartz
AAM Statement on President Biden’s Supply Chain Executive Order
Press Release
Feb 24, 2021
| Rachel Schwartz
AAM Announces 2021 Board of Directors
Press Release
Feb 24, 2021
| Rachel Schwartz
AAM Announces 2021 Associate Members
Report
Feb 22, 2021
| Erica Klinger
Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets
Press Release
Feb 22, 2021
| Rachel Schwartz
AAM Outlines Policy Solutions for Sustained Patient Access to Generic and Biosimilar Medicines
Press Release
Feb 19, 2021
| Rachel Schwartz
AAM Statement on President Biden’s Nomination of Chiquita Brooks-LaSure as CMS Administrator
Press Release
Feb 9, 2021
| Rachel Schwartz
Complex Generics Could Save the U.S. Health Care System Approximately $1.3 Billion Per Year
Report
Feb 9, 2021
| Erica Klinger
White Paper: Potential Savings from Accelerating U.S. Approval of Complex Generics
Blog
Feb 5, 2021
| Erica Klinger
Cancer Costs and Options for Care in the United States
Blog
Feb 4, 2021
| Dan Leonard
While We Await the Vaccine, We Can Trust in Generic Drugs
Blog
Jan 29, 2021
| Kristin Murphy
AAM’s Recommendations to #SecureOurMeds
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2024
GRx+Biosims 2023
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action